Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

custirsen

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

OGX-011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
BACKGROUND Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors such as… Expand
2017
2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel…
BACKGROUND Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration… Expand
2017
2017
A population pharmacokinetic meta‐analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects
AIMS Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under… Expand
  • table 2
  • figure 1
  • figure 3
  • figure 2
  • figure 4
2015
2015
Phase III SYNERGY trial: Docetaxel +/- custirsen and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and poor prognosis.
5009 Background: Clusterin is a chaperone protein associated with treatment resistance and upregulated by apoptotic stressors… Expand
2015
2015
Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.
AIMS Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide (ASO) that reduces clusterin production, is under… Expand
2013
2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
Elevated levels of clusterin (CLU), a stress‐induced and secreted cytoprotective chaperone, are associated with advanced tumor… Expand
Highly Cited
2012
Highly Cited
2012
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
Purpose: Clusterin (CLU), an antiapoptotic, stress-associated protein, confers resistance to therapy when overexpressed. This… Expand
Highly Cited
2011
Highly Cited
2011
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after…
Purpose: Clusterin (CLU) is an antiapoptotic, stress-induced protein conferring treatment resistance when overexpressed. This… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2011
2011
SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
TPS180 Background: Custirsen (OGX-011) is a second generation antisense oligonucleotide (ASO) with a prolonged tissue half-life… Expand
2008
2008
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel…
5002 Background: There is no standard of care when pts with metastatic HRPC manifest disease progression (PD) after 1st-line… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE